Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phenoxypropazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.59 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SCN4A | P35499 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenoxypropazine SCHEMBL6064655 | 0.98 | MAOA (0.96) | MAOAPTGS1MTNR1AMTNR1BLMNA | |
| Phenoxypropazine SCHEMBL6874344 | 0.98 | MAOA (0.96) | MAOAPTGS1MTNR1AMTNR1BLMNA | |
| Phenoxypropazine SCHEMBL4034660 | 0.98 | MAOA (0.96) | MAOAPTGS1MTNR1AMTNR1BLMNA | |
| Phenoxypropazine SCHEMBL5776663 | 0.93 | MAOA (0.86) | MAOAPTGS1MTNR1AMTNR1BLMNA | |
| Phenoxypropazine SCHEMBL20268628 | 0.86 | MAOA (0.73) | MAOAPTGS1MTNR1AMTNR1BLMNA | |
| SCHEMBL13212031 | 0.82 | MAOA (0.69) | MAOAPTGS1MTNR1AMTNR1BLMNA | |
| SCHEMBL11598862 | 0.82 | MAOA (0.69) | MAOAPTGS1MTNR1AMTNR1BLMNA | |
| SCHEMBL13996939 | 0.80 | MAOA (0.67) | MAOAPTGS1MTNR1AMTNR1BLMNA | |
| SCHEMBL11463788 | 0.79 | MAOA (0.65) | MAOAPTGS1MTNR1AMTNR1BLMNA | |
| SCHEMBL20385338 | 0.78 | MAOA (0.65) | MAOAPTGS1MTNR1AMTNR1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 654 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | Natural MedTech Pty Ltd (AU) | 2025-11-06 | — | — | US | claimed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4525870-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | Corcept Therapeutics Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| EP-4479032-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | Sage Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| US-12121513-B2 | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | Intrabio Ltd. (GB) | 2024-10-22 | — | — | US | claimed |
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-07-25 | — | — | US | claimed |
| WO-2024108195-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024098098-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural MedTech Pty Ltd (AU) | 2024-05-16 | — | — | WO | claimed |
| WO-2004041207-A2 | GHB TREATMENT METHODS | BAYLOR RESEARCH INSTITUTE (US) | 2004-05-21 | — | — | WO | claimed |
| WO-2001070419-A1 | METHOD FOR FABRICATING SUPPORTED BILAYER-LIPID MEMBRANES | CORNING INCORPORATED (US) | 2001-09-27 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1999013499-A2 | IN-SITU ACCEPTOR ACTIVATION IN GROUP III-V NITRIDE COMPOUND SEMICONDUCTORS | SDL, INC. (US) | 1999-03-18 | — | — | WO | claimed |
| EP-0536343-A1 | TARGETED POLYMERIC CONJUGATES OF CYCLOSPORIN AND METHOD FOR THEIR PREPARATION. | GALENA (CS) | 1993-04-14 | — | — | EP | claimed |
| WO-1992013569-A1 | TARGETED POLYMERIC CONJUGATES OF CYCLOSPORIN AND METHOD FOR THEIR PREPARATION | GALENA (CS) | 1992-08-20 | — | — | WO | claimed |
| EP-0351262-A1 | Polysilazanes, their preparation and use as precursors for ceramic materials, and the ceramic materials | ELF ATOCHEM S.A. (FR) | 1990-01-17 | — | — | EP | claimed |
| EP-0086046-A1 | A process for the preparation of alpha-6-DEOXYTETRACYCLINES | PLURICHEMIE ANSTALT (LI) | 1983-08-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CYP3A43, NR3C2, CYP3A5 | MAOA 2517/4885PTGS1 675/4885MTNR1A 311/4885 |
| US-12121513-B2 | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | HNMT, MAOA, MAOB | MAOA 2/4885PTGS1 1061/4885MTNR1A 686/4885 |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | MAOA, MAOB, TPH1 | MAOA 1/4885PTGS1 1297/4885MTNR1A 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.